Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Liabilities: 2013-2024

Historic Total Liabilities for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $871.1 million.

  • ImmunityBio's Total Liabilities fell 5.98% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 5.98%. This contributed to the annual value of $871.1 million for FY2024, which is 20.11% down from last year.
  • ImmunityBio's Total Liabilities amounted to $871.1 million in FY2024, which was down 20.11% from $1.1 billion recorded in FY2023.
  • In the past 5 years, ImmunityBio's Total Liabilities ranged from a high of $1.1 billion in FY2023 and a low of $339.9 million during FY2020.
  • Over the past 3 years, ImmunityBio's median Total Liabilities value was $871.1 million (recorded in 2024), while the average stood at $924.5 million.
  • Per our database at Business Quant, ImmunityBio's Total Liabilities skyrocketed by 1,414.31% in 2020 and then fell by 20.11% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Total Liabilities stood at $339.9 million in 2020, then skyrocketed by 109.73% to $712.8 million in 2021, then climbed by 13.94% to $812.2 million in 2022, then skyrocketed by 34.26% to $1.1 billion in 2023, then fell by 20.11% to $871.1 million in 2024.